Different routes to join and partner with IMI2

Irene Norstedt
Head of Unit – Innovative and Personalised Medicine
DG RTD, European Commission

Magda Chlebus
Director Science Policy, EFPIA

Brussels, 26 November 2014
IMI – Europe’s partnership for health

**IMI1 programme**
2008-2013
- €2 bn budget
- 11 Calls for proposals
- 60+ projects

**IMI2 programme**
2014-2024
- Larger budget
- Ambitious Strategic Research Agenda
- Open to other industries

**IMI2 total budget**
€3.28 bn

**IMI2**
- €1.638 bn
- €1.425 bn
- Other €213 m
1. Participant in IMI2 projects

IMI2 total budget
€3.28 bn

- €1.638 bn
  - EFPIA
- €1.425 bn
  - Other
- €213 m
1. Participant in IMI2 projects

- Any entity carrying out work relevant to the IMI2 objectives may participate, provided that:
  - At least three legal entities, each established in a different Member State or an associated country (minimum condition for standard collaborative actions)
  - Potential additional conditions in the annual work plan (and Call documents) are fulfilled
1. Participant in IMI2 projects

- Only beneficiaries established in a EU Member State / H2020 Associated Country are eligible for EU funding, unless:
  - Participation is deemed essential by the JU for carrying out the action, or
  - Additional conditions are set in the annual Work Plan/Calls documents

- More types of entities are eligible for EU funding under IMI2 than under IMI1:
  - Academic institutions
  - Research organisations
  - Small & medium-sized enterprises (SMEs)
  - NEW: Mid-sized enterprises (≤ 500M)
  - Non-profit patient organisations
  - Non-profit public bodies and intergovernmental organisations including specialised agencies
2. IMI2 Associated Partner

IMI2 total budget
€3.28 bn

€1.638 bn

€1.425 bn

Other
€213 m
2. IMI2 Associated Partner

- IMI2 is open to participation from organisations beyond the pharmaceutical companies represented by EFPIA
  - ICT, diagnostics, imaging, animal health, etc.

- Any legal entity other than a Member or a constituent/affiliated entity of a Member, may apply to join IMI2 as an Associated Partner
  - Entity supporting the objectives of the IMI2 Joint Undertaking in its specific area of research;
  - Upon acceptance of the IMI2 Statutes by a letter of endorsement, that details the scope of the association in terms of contribution (in-kind or in-cash), activities and duration;
  - Application to be addressed to the IMI2 Governing Board
2. Examples

- **Associated Partners:**
  - Call 1, topic 1 "Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)"
  - The **Juvenile Diabetes Research Foundation (JDRF)** will contribute €2.8 million
  - **Leona M. and Harry B. Helmsley Charitable Trust** will contribute a further €2.2 million
  - Up-coming call 3: **Bill and Melinda Gates Foundation** will contribute to a topic on Pertussis Vaccination research
3. EFPIA direct or indirect Member

IMI2 total budget
€3.28 bn

€1.638 bn

€1.425 bn

Other
€213 m
IMI2 vision – towards integrated healthcare solutions

- Addressing healthcare priorities identified by the WHO 2013 report
- Strategic Research Agenda aimed at progressing the vision of stratified medicines: prevention, treatment and health management
- Entire product cycle from discovery, through development to healthcare delivery and access models
- Collaboration across sectors to harness all knowledge and technologies which can contribute to IMI2 vision - diagnostics, imaging, IT, medical devices, ...
Engaging in IMI2 activities as EFPIA director or indirect member

- Affiliated entities of an EFPIA corporate member, EFPIA specialized group (Vaccines Europe or EBE) or member of an EFPIA association

- and EFPIA Partner in Research
  - Non-pharmaceutical companies, e.g. imaging, medical information technology, diagnostic, animal health industries, ...
  - GE HealthCare, Zeiss, Zoetis, PMB Alcen, Alcediag joined in 2014
<table>
<thead>
<tr>
<th></th>
<th>EFPIA Partners in Research</th>
<th>IMI Associated Partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact on IMI2 strategy</td>
<td>Yes[1]</td>
<td>No</td>
</tr>
<tr>
<td>Access to and impact on the shape of IMI initiatives</td>
<td>Programme level and/or project-by-project</td>
<td>Project-by-project</td>
</tr>
<tr>
<td>Impact on IMI governance</td>
<td>Yes[2]</td>
<td>No</td>
</tr>
<tr>
<td>Contribution to IMI administrative costs</td>
<td>Yes[3]</td>
<td>No</td>
</tr>
<tr>
<td>Impact on EFPIA research and life science policy</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Access to industry support group (Industry Liaison Group)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>EU budget available to match industry contributions until 2024</td>
<td>1,425 mln</td>
<td>213 mln</td>
</tr>
<tr>
<td>Ability to run sectorial projects (without pharmaceutical industry)</td>
<td>Yes - for developing tools necessary in other IMI projects</td>
<td>Yes</td>
</tr>
<tr>
<td>Ability to contribute to ongoing IMI1 projects with EU matching funding for public partners</td>
<td>Yes, with IMI matching (if budget available)</td>
<td>Yes, but without IMI matching</td>
</tr>
</tbody>
</table>

[1] Through thematic Strategic Governing Groups and/or RDG
[2] Through EFPIA - contribution to “one industry voice” expressed by industry representation on IMI Governing Board
[3] 3% of company contribution with minimum contribution of 5, 10 or 20 K depending on European sales and cap set at the level of comparable size EFPIA company
Interested to get more information?

EFPIA Partner in Research
Contact: magda.chlebus@efpia.eu & katharina.angrosch@efpia.eu
4. IMI2 Member

- **According to the Statutes of IMI2:** "Any legal entity that directly or indirectly supports research and innovation in a Member State or in a country associated with the Horizon 2020 Framework Programme may apply to become a Member of the IMI2 Joint Undertaking."

- Application to be addressed **to the IMI2 Governing Board** accompanied by a proposal to adapt the composition of the Governing Board
Key messages

- **IMI2** expands the scope of IMI1 to cover the entire medical research and innovation value chain

- **Involving all relevant partners:** pharmaceutical and other health-related industries, patients, academia, SMEs, regulators, in open innovation networks
  - Open to participation from industries beyond the pharmaceutical companies
  - More entities eligible for EU funding: medium-sized industrial partners (annual sales less than €500 million)